ERC Awards €150,000 Proof of Concept Grant to Gustave Roussy's Nano-BITE Project for Nanomedicine-Enhanced Immunotherapy Against Solid Tumors
核心洞察
Alexandre Detappe (搜索) of Gustave Roussy (搜索) receives a highly selective ERC Proof of Concept grant worth €150,000 over 18 months for the Nano-BITE project.
The project aims to develop nanoparticles that direct and sustain immune responses within the tumor microenvironment, overcoming two major barriers to solid tumor immunotherapy.
The approach seeks to concentrate therapeutic activity at the tumor site while limiting effects on healthy tissues, potentially enabling more targeted, effective, and better-tolerated immunotherapies.
The European Research Council (ERC) has awarded a Proof of Concept grant to Alexandre Detappe (搜索), Head of the Nanomedicine Team at Gustave Roussy (搜索), for his Nano-BITE project—an innovative approach that leverages nanomedicine to enhance immunotherapy against solid tumors (搜索). The grant, worth €150,000 over 18 months, is among only 182 projects selected across Europe and 18 in France, underscoring the highly competitive nature of this funding scheme.
The ERC Proof of Concept grant is reserved for researchers who have previously received an ERC Starting Grant and is designed to support the maturation and valorization of promising scientific results, facilitating their transfer into practical applications.
Overcoming Two Major Barriers in Solid Tumor Immunotherapy
Immunotherapy has profoundly transformed cancer treatment by mobilizing the immune system against tumor cells. Despite these advances, its effectiveness remains limited in many solid tumors (搜索) due to two persistent obstacles. First, attracting sufficient immune cells to the tumor site is often difficult. Second, these cells struggle to remain durably active within the particularly hostile tumor microenvironment. These limitations reduce treatment effectiveness and may necessitate repeated administrations, increasing the risk of side effects.
The Nano-BITE Approach: Precision Through Nanomedicine
The Nano-BITE project addresses these challenges by developing nanoparticles capable of acting directly within the tumor microenvironment. The objective is to promote interactions between immune cells and cancer cells while maintaining a durable antitumor response. This strategy could concentrate therapeutic activity at the tumor site while limiting effects on healthy tissues.
"With Nano-BITE, we aim to harness the potential of nanomedicine to make immunotherapy more precise and more effective against solid tumors (搜索). This prestigious funding will enable us to take a decisive step toward validating this innovative approach," said Alexandre Detappe (搜索).
Path Toward Clinical Translation
Over the next 18 months, the ERC-funded work will deliver the first preclinical validations of this technology and prepare its next stages of development. Ultimately, this strategy could pave the way for new treatments for patients with solid tumors (搜索), drawing on the expertise of Gustave Roussy (搜索)'s Department of Therapeutic Innovation and Early Phase Trials (DITEP).
Alexandre Detappe (搜索) holds the Gustave Roussy (搜索) Foundation Chair of Excellence in Nanotherapy and leads the Nanomedicine Team at Gustave Roussy (Inserm U1363, Université Paris-Saclay) as well as the Nanomedicine laboratory at Institut Strauss. The project is supported by ERC Proof of Concept Grant #101335332.